FIELD: biotechnology.
SUBSTANCE: variants of a method for enhancing immunity in a human patient that is in need of immunity enhancing are proposed. The methods include administering an anti-TIM-3 antibody and an anti-PD-1 antibody to a patient. Also a pharmaceutical composition for enhancing immunity and treating cancer, containing an antibody to TIM-3 or an antigen-binding portion thereof and an antibody to PD-1 or an antigen-binding portion thereof are provided.
EFFECT: invention provides enhanced immunity with significantly increased efficiency and can be used in cancer therapy.
19 cl, 13 dwg, 9 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| MULTIVALENT AND MULTISPECIFIC HYBRID PROTEINS THAT BIND TO DR5 | 2016 |
|
RU2748620C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
